Oral anticoagulation in chronic kidney disease: A huge challenge

References
1 Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med 2006; 354: 997-999.
2 Soliman EZ, Prineas RJ, Go AS. et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159: 1102-1107.
3 Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011; 57: 1339-1348.
4 Baber U, Howard VJ, Halperin JL. et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 2011; 04: 26-32.
5 Ronco C, Haapio M, House AA. et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539.
6 Iguchi Y, Kimura K, Kobayashi K. et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008; 102: 1056-1059.
7 Go AS, Fang MC, Udaltsova N. et al. ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363-1369.
8 Marinigh R, Lip GY, Fiotti N. et al. Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis: Implications for thromboprophylaxis. J Am Coll Cardiol 2010; 56: 827-837.
9 Singer DE, Chang Y, Fang MC. et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
10 Olesen JB, Lip GY, Lindhardsen J. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
11 Falgá C, Capdevila JA, Soler S. et al. RIETE Investigators. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost 2007; 98: 771-776.
12 Gallego P, Roldán V, Torregrosa JM. et al. Relation of the Has-Bled Bleeding Risk Score to Major Bleeding, Cardiovascular Events and Mortality in Anticoagulated Patients with Atrial Fibrillation. Circ Arrhythm Electrophysiol 2012; 05: 312-318.
13 Dimarco JP, Flaker G, Waldo AL. et al. AFFIRM Investigators Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005; 149: 650-656.
14 Manzano-Fernández S, Cambronero F, Caro-Martínez C. et al. Mild kidney disease as a risk factor for major bleeding in patientswith atrial fibrillation undergoing percutaneous coronary stenting. Thromb Haemost 2012; 107: 51-58.
15 Pisters R, Lane DA, Nieuwlaat R. et al. A novel userfriendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010; 138: 1093-1100.
16 Lip GY, Andreotti F, Fauchier L. et al. European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
17 Camm AJ, Kirchhof P, Lip GY. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
18 Gage BF, Yan Y, Milligan PE. et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-719.
19 Fang MC, Go AS, Chang Y. et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58: 395-401.
20 Ruíz-Giménez N, Suárez C, González R. et al. RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 26-31.
21 Poli D, Antonucci E, Zanazzi M. et al. Impact of glomerular filtration on bleeding risk in very old patients treated with VKA: Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Haemost 2012; 107: 1100-1106.
22 Van Pottelbergh G, Van Heden L, Matheï C. et al. Methods to evaluate renal function in elderly patients: a systematic literature review. Age Ageing 2010; 39: 542-548.
23 Zamora E, Lupón J, Vila J. et al. Estimated glomerular filtration rate and prognosis in heart failure: value of the modification of diet in renal disease study-4, chronic kidney disease epidemiology collaboration, and cockroft-gault formulas. J Am Coll Cardiol 2012; 59: 1709-1715.
24 Kooiman J, van de Peppel WR, van der Meer FJ. et al. Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. J Thromb Haemost 2011; 09: 1652-1653.
25 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etxilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
26 Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?. Thromb Haemost 2011; 105: 574-578.
27 Limdi NA, Beasley TM, Baird MF. et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20: 912-921.
28 Poli D, Antonucci E, Marcucci R. et al. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res 2007; 121: 347-352.
29 Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and Thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103: 683-685.
30 Wizemann V, Tong L, Satayathum S. et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77: 1098-1106.
31 Reinecke H, Brand E, Mesters R. et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20: 705-711.
32 Vázquez E, Sánchez-Perales C, Lozano C. et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 2003; 92: 868-871.
33 Yang F, Chou D, Schweitzer P. et al. Warfarin in haemodialysis patients with atrial fibrillation: what benefit?. Europace 2010; 12: 1666-1672.
34 Harder S. Renal Profiles of Anticoagulants. J Clin Pharmacol. 2011 epub ahead of print.
35 Hart RG, Pearce LA, Asinger RW. et al. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 06: 2599-2604.
36 Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125: 2298-2307.